Gilde Healthcare Partners and Lightstone Ventures led a €30m Series A funding round in ProVerum.

Venture capital firms Gilde Healthcare Partners and Lightstone Ventures led a €30m Series A funding round in ProVerum, a developer of a diagnosis device. "We are delighted to have Dave join the ProVerum Board, his knowledge, understanding and experience in this field validates the commercial potential of the ProVee system. The strong investor support from both Gilde Healthcare and Lightstone Ventures further underscores the opportunity and the progress ProVerum has made thus far. We are looking forward to bringing our patient-friendly solution to market in order to offer BPH sufferers a simple, safe and effective treatment in the doctor's office," Paul Bateman, ProVerum CEO.